Regeneron's Eylea combination therapy fails mid-stage study

Regeneron's Eylea combination therapy fails mid-stage study


Regeneron Pharmaceuticals Inc said a combination therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet age-related macular degeneration , a leading cause of blindness. Patients who received the combination of Eylea and experimental antibody rinucumab experienced a 5.8 letter improvement on a scale designed to evaluate visual clarity, compared with a 7.5 letter improvement in those who were given Eylea alone.



from Biotech News